The drug candidate LIB-01

The overall goal is to develop LIB-01 into a registered drug on the world market, that treats erectile dysfunction and premature ejaculation better than currently available drugs.

A preclinical development program is currently underway, studying the pharmacology and kinetics of the drug substance as well as a comprehensive safety evaluation in order to investigate possible toxic effects in LIB-01. Within the development program, process development and manufacturing are also carried out to ensure availability of the drug substance. The drug substance together with a formulation, constitute the drug product that will be used in the first clinical human trial. All of these preclinical activities must be completed before the application to begin a phase 1 clinical trial can be compiled. The first clinical studies in human are planned to start in mid-2023.

Development plan